DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Respiratory Physiology & Neurobiology Année : 2020

DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension

Résumé

The ratio of the diffusing capacity of the lung for carbon monoxide (DLCO) and for nitric oxide (DLNO) measured simultaneously is modified in patients with precapillary pulmonary hypertension (PH). The potential impact of targeted therapy on the DLCO/DLNO ratio is unknown. Simultaneous measurements of DLNO and DLCO were performed at baseline, 3-4 month follow-up (first evaluation) and 12-month follow-up (second evaluation) after initiation of targeted PH therapies in incident cases of precapillary PH. The main outcome was the change in DLNO/DLCO ratio under treatment between baseline and the first evaluation. Twenty-nine patients were included (mean age: 66.8 years, 62.1% female). No significant change in the DLNO/DLCO ratio was found between baseline and the first evaluation. Similarly, no significant differences were noted with regard to changes in Dm or Vc, the DLNO/DLCO ratio in different patient subgroups, or in the 20 patients evaluated at the second follow-up. Within the limitations of this study, the DLNO/DLCO ratio is not useful in monitoring the response to treatment in PH.

Dates et versions

hal-03036197 , version 1 (02-12-2020)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

J. Catella, F. Costes, Jb Gaultier, I. Court Fortune, C. Tulane, et al.. DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension. Respiratory Physiology & Neurobiology, 2020, 279, pp.103467. ⟨10.1016/j.resp.2020.103467⟩. ⟨hal-03036197⟩
75 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More